Skip to main content

Effects of interference with GATA-3 expression by target-specific DNAzyme treatment on disease progression in a subacute oxazolone-induced mouse model of atopic dermatitis


DNAzymes represent a particular class of antisense molecules combining the specificity of antisense molecules with an inherent catalytic cleavage activity, which makes them an attractive tool for highly specific interference with target RNA molecules. In general, they are single-stranded DNA molecules with sequence-specific RNA-binding domains flanking a central catalytic domain. We developed and patented a DNAzyme - named hgd40 – that targets the mRNA for GATA-3, the central transcription factor in T helper cell type 2 (Th2) differentiation and activation. For penetration enhancement and DNAzyme protection a specific water/oil/water emulsion for topical dermal application was developed and patented. Targeting GATA-3 might be a key for therapeutic intervention in predominantly Th2-driven diseases like atopic dermatitis.


The therapeutic effects of hgd40 were analyzed in an oxazolone-induced dermatitis model modified to establish elongated skin swelling reactions, thereby enabling the analysis of treatment effects on T cell-mediated pathomechanisms.


Treatment with topically applied hgd40 water/oil/water emulsion significantly and dose-dependently reduced oxazolone-induced skinfold thickness and suppressed infiltration of CD4+ T cells into the skin. Molecular analysis revealed reduced GATA-3 mRNA levels early during disease progression.


In summary, targeting GATA-3 by DNAzyme treatment may represent a new and promising therapeutic agent for the topical treatment of allergic skin diseases.

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibrahim, R., Purath, U., Turowska, A. et al. Effects of interference with GATA-3 expression by target-specific DNAzyme treatment on disease progression in a subacute oxazolone-induced mouse model of atopic dermatitis. Clin Transl Allergy 5 (Suppl 1), O21 (2015).

Download citation

  • Published:

  • DOI:


  • Atopic Dermatitis
  • Skinfold Thickness
  • Promising Therapeutic Agent
  • Dermal Application
  • Helper Cell Type